
    
      A 6-month, Randomised, Double-blind, Placebo-controlled, Multi-centre, Parallel-group, Phase
      II Study with an Optional Safety Extension Treatment Period up to 6 months, to Evaluate the
      Efficacy, Safety, and Tolerability of 3 Different Doses of AZD5069 Twice Daily as Add-on
      Treatment to Medium to High Dose Inhaled Corticosteroids (ICS) and Long-acting Î²2 Agonists
      (LABA), in Patients with Uncontrolled Persistent Asthma
    
  